The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.
 
Xiangrui Meng
No Relationships to Disclose
 
Junsheng Wang
No Relationships to Disclose
 
Jin Xia
No Relationships to Disclose
 
Tao Wu
No Relationships to Disclose
 
Zhiquan Luo
No Relationships to Disclose
 
Yong-Gui Hong
No Relationships to Disclose
 
Ping Lu
No Relationships to Disclose
 
Yanzhen Guo
No Relationships to Disclose
 
Yinghua Ji
Research Funding - AoSaiKang (Inst); CSPC Pharmaceutical Group (Inst); Hualan Bio (Inst)
 
Min Zhang
No Relationships to Disclose
 
Liuzhong Yang
No Relationships to Disclose
 
Peng Cheng
No Relationships to Disclose
 
Wenchang Liang
No Relationships to Disclose
 
Zhengzheng Shan
No Relationships to Disclose
 
Qingxia Fan
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose